GSK at ESMO 2023
GSK will share data presentations describing new findings and progress in our oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2023. This research reflects our commitment to maximising patient survival through transformational medicines, with a current focus on breakthroughs in immuno-oncology and tumor-cell targeting therapies, and the application of these approaches in gynaecologic cancers and other solid tumours.
Patient stories
Connecting with the myelofibrosis care partner and patient community
We recently launched Mapping Myelofibrosis, an initiative designed to provide information about this complex blood cancer and support the myelofibrosis patient community. This initiative will connect myelofibrosis patients and caregivers with educational tools, resources and stories to help navigate their journey, from the onset of symptoms through diagnosis and disease management.
We are proud to have recently launched the first episode of our podcast series, featuring an interview with Cheryl Petruk, the Founder of the Canadian MPN Research Foundation and Executive Director of the Canadian MPN Network, discussing the role of care partners in supporting those with myelofibrosis.
Listen to our first podcast episode - Mapping Myelofibrosis: A caregiver’s journey
Targeting a better future for multiple myeloma patients
GSK is driving progress for the multiple myeloma community by identifying and accelerating innovative ideas. This year, through our Target the Future Think Tank Challenge, GSK will provide an £85,000 ($100,000) grant to the most innovative approach to address disparities multiple myeloma patients face. Our judging panel is currently evaluating submissions from around the world. Learn more about the programme on the Target the Future site, and follow along for exciting updates on the finalists and selected grantee on our social channels.
Go behind the science
Discover how we’re uniting technology, science, and talent to get ahead of cancer and advance a new generation of cancer therapies.
